HLX-26 Drug Asset Due Diligence Report 2026

This HLX-26 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether HLX-26 can convert its Monoclonal antibody profile and LAG3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	HLX-26 (query alias: HLX-26)
Modality / target	Monoclonal antibody; LAG3; LAG3 inhibitors
Highest global status	Phase 2
Originator	Shanghai Henlius Biotech, Inc.
Active developers	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., Shanghai Henlius Biopharmaceuticals Co. , Ltd., Shanghai Henlius Biotech, Inc.

The MCP disease footprint includes Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, metastatic non-small cell lung cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05787613	Phase 2	Active, not recruiting	132	Primary endpoint not disclosed in English source
NCT05584137	Phase 2	Terminated	2	Primary endpoint not disclosed in English source
NCT05400265	Phase 1	Completed	9	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors

Phase 1; n=27; evaluation: Positive. Reported fields: MTD = NR ; MTD = NR

Safety, tolerability, and pharmacokinetics of HLX26 (an anti-LAG3 antibody) in patients with advanced or metastatic solid tumors or lymphomas.

Phase 1; n=12; evaluation: Positive. Reported fields: DLT = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

HLX-26 addresses Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, metastatic non-small cell lung cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 28 matched transaction record(s) under the scope “target-level comparable: LAG3.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: LAG3 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-19	Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program	Discovery	Financial terms not disclosed
2025-12-08	Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	Phase 3	US$20.0M upfront; US$349.5M milestones
2025-02-04	Agenus received formal notice from Incyte electing to terminate the License, Development, and Commercialization Agreement	Phase 2	US$25.0M upfront; US$510.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO